Drug Profile
BNC 1021
Alternative Names: BNC-1021; PK-7010; TRK-250Latest Information Update: 08 Jul 2023
Price :
$50
*
At a glance
- Originator BONAC Corporation
- Developer BONAC Corporation; Toray
- Class Antifibrotics; Nucleic acids; Oligonucleotides; Small interfering RNA
- Mechanism of Action RNA interference; Transforming growth factor beta1 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 19 May 2023 Adverse events data from a phase I trial in Idiopathic pulmonary fibrosis presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 01 Apr 2022 Torray completes a phase I trial in Idiopathic pulmonary fibrosis in USA (NCT03727802)
- 14 May 2021 Preclinical trials in Idiopathic pulmonary fibrosis in Japan (Intrathecal)